Evidence mapPaperPMID 35644117Full record

ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2022

Reviving the mutual impact of SARS-COV-2 and obesity on patients: From morbidity to mortality.

Tapan Behl, Sachin Kumar, Sukhbir Singh, Saurabh Bhatia, Ali Albarrati, Mohammed Albratty, Abdulkarim M Meraya, Asim Najmi, Simona Bungau

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. The Pharmacological Efficacy of Baicalin in Inflammatory Diseases.International journal of molecular sciences · 2023
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Tapan BehlChitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India. Electronic address: tapanbehl31@gmail.com.
Sachin KumarChitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
Sukhbir SinghChitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
Saurabh BhatiaNatural & Medical Sciences Research Centre, University of Nizwa, Birkat Al Mauz, Nizwa, Oman; School of Health Science, University of Petroleum and Energy Studies, Dehradun, Uttarakhand, India.
Ali AlbarratiRehabilitation Health Sciences College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Mohammed AlbrattyDepartment of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
Abdulkarim M MerayaPharmacy Practice Research Unit, Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
Asim NajmiDepartment of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
Simona BungauDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania; Doctoral School of Biomedical Sciences, University of Oradea, Oradea, Romania. Electronic address: simonabungau@gmail.com.
Chitkara University · INJazan University · SAKing Saud University · SAUniversity of Nizwa · OMUniversity of Oradea · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity-related metabolic dysfunction, endothelium imbalance, chronic inflammation, immune dysregulation, and its comorbidities may all have a role in systemic inflammation, leading to the pulmonary fibrosis and cytokine storm, which leads to failure of lung function, which is a hallmark of severe SARS-CoV-2 infection. Obesity may also disrupt the function of mucociliary escalators and cooperation of epithelial cell's motile cilia in the airway, limiting the clearance of the coronavirus that causes severe acute respiratory syndrome (SARS-CoV-2). Adipose tissues in obese patients have a greater number of proteases and receptors for SARS-CoV-2 admittance, proposing that they could serve as an accelerator and reservoir for this virus, boosting immunological response and systemic inflammation. Lastly, anti-inflammatory cytokines such as anti-IL-6 and the infusion of mesenchymal stem cells could be used as a modulation therapy of immunity to help COVID-19 patients. Obesity, on the other hand, is linked to the progress of COVID-19 through a variety of molecular pathways, and obese people are part of the SARS-CoV-2 susceptible individuals, necessitating more protective measures.

Indexed as

COVID-19SARS-CoV-2HumansInflammationMorbidityObesityInflammationObesityPandemicRespiratory complianceSARS-CoV-2

Identifiers

PMID35644117
PMCPMC9127128
OpenAlexW4281388141

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.